215 related articles for article (PubMed ID: 27420181)
1. Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients.
Drelichman G; Fernández Escobar N; Basack N; Aversa L; Larroude MS; Aguilar G; Szlago M; Schenone A; Fynn A; Cuello MF; Aznar M; Fernández R; Ruiz A; Reichel P; Guelbert N; Robledo H; Watman N; Bolesina M; Elena G; Veber SE; Pujal G; Galván G; Chain JJ; Arizo A; Bietti J; Bar D; Dragosky M; Marquez M; Feldman L; Muller K; Zirone S; Buchovsky G; Lanza V; Sanabria A; Fernández I; Jaureguiberry R; Contte M; Barbieri María A; Maro A; Zárate G; Fernández G; Rapetti MC; Donato H; Degano A; Kantor G; Albina R; Á Lvarez Bollea M; Brun M; Bacciedoni V; Del Río F; Soberón B; Boido N; Schweri M; Borchichi S; Welsh V; Corrales M; Cedola A; Carvani A; Diez B; Richard L; Baduel C; Nuñez G; Colimodio R; Barazzutti L; Medici H; Meschengieser S; Damiani G; Nucifora M; Girardi B; Gómez S; Papucci M; Verón D; Quiroga L; Carro G; De Ambrosio P; Ferro J; Pujol M; Castella CC; Franco L; Nisnovich G; Veloso M; Pacheco I; Savarino M; Marino A; Saavedra JL
Am J Hematol; 2016 Oct; 91(10):E448-53. PubMed ID: 27420181
[TBL] [Abstract][Full Text] [Related]
2. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
Mistry PK; Deegan P; Vellodi A; Cole JA; Yeh M; Weinreb NJ
Br J Haematol; 2009 Nov; 147(4):561-70. PubMed ID: 19732054
[TBL] [Abstract][Full Text] [Related]
3. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Mistry PK; Batista JL; Andersson HC; Balwani M; Burrow TA; Charrow J; Kaplan P; Khan A; Kishnani PS; Kolodny EH; Rosenbloom B; Scott CR; Weinreb N
Am J Hematol; 2017 Sep; 92(9):929-939. PubMed ID: 28569047
[TBL] [Abstract][Full Text] [Related]
4. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
[TBL] [Abstract][Full Text] [Related]
5. Bone complications in children with Gaucher disease.
Bembi B; Ciana G; Mengel E; Terk MR; Martini C; Wenstrup RJ
Br J Radiol; 2002; 75 Suppl 1():A37-44. PubMed ID: 12036831
[TBL] [Abstract][Full Text] [Related]
6. A Comprehensive Study of Bone Manifestations in Adult Gaucher Disease Type 1 Patients in Argentina.
Oliveri B; González D; Quiroga F; Silva C; Rozenfeld P
Calcif Tissue Int; 2019 Jun; 104(6):650-657. PubMed ID: 30790003
[TBL] [Abstract][Full Text] [Related]
7. Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy.
Potnis KC; Flueckinger LB; Ha CI; Upadia J; Frush DP; Kishnani PS
Mol Genet Metab; 2019 Feb; 126(2):157-161. PubMed ID: 30448006
[TBL] [Abstract][Full Text] [Related]
8. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
9. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
Piran S; Roberts A; Patterson MA; Amato D
Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
[TBL] [Abstract][Full Text] [Related]
10. Skeletal involvement in type 1 Gaucher disease: Not just bone mineral density.
Baldini M; Casirati G; Ulivieri FM; Cassinerio E; Khouri Chalouhi K; Poggiali E; Borin L; Burghignoli V; Cesana BM; Cappellini MD
Blood Cells Mol Dis; 2018 Feb; 68():148-152. PubMed ID: 28693786
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Khan A; Hangartner T; Weinreb NJ; Taylor JS; Mistry PK
J Bone Miner Res; 2012 Aug; 27(8):1839-48. PubMed ID: 22692814
[TBL] [Abstract][Full Text] [Related]
12. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy.
Deegan PB; Pavlova E; Tindall J; Stein PE; Bearcroft P; Mehta A; Hughes D; Wraith JE; Cox TM
Medicine (Baltimore); 2011 Jan; 90(1):52-60. PubMed ID: 21200186
[TBL] [Abstract][Full Text] [Related]
13. The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients.
Deegan P; Khan A; Camelo JS; Batista JL; Weinreb N
Orphanet J Rare Dis; 2021 Feb; 16(1):92. PubMed ID: 33602299
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease.
Andrade-Campos M; Alfonso P; Irun P; Armstrong J; Calvo C; Dalmau J; Domingo MR; Barbera JL; Cano H; Fernandez-Galán MA; Franco R; Gracia I; Gracia-Antequera M; Ibañez A; Lendinez F; Madruga M; Martin-Hernández E; O'Callaghan MDM; Del Soto AP; Del Prado YR; Sancho-Val I; Sanjurjo P; Pocovi M; Giraldo P
Orphanet J Rare Dis; 2017 May; 12(1):84. PubMed ID: 28468677
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients.
El-Beshlawy A; Ragab L; Youssry I; Yakout K; El-Kiki H; Eid K; Mansour IM; Abd El-Hamid S; Yang M; Mistry PK
J Inherit Metab Dis; 2006 Feb; 29(1):92-8. PubMed ID: 16601874
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic approaches to bone pathology in Gaucher disease: past, present and future.
Goker-Alpan O
Mol Genet Metab; 2011 Dec; 104(4):438-47. PubMed ID: 21889384
[TBL] [Abstract][Full Text] [Related]
17. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.
Lebel E; Elstein D; Peleg A; Reinus C; Zimran A; Amir G
Am J Clin Pathol; 2013 Jul; 140(1):91-6. PubMed ID: 23765538
[TBL] [Abstract][Full Text] [Related]
18. The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease.
Gervas-Arruga J; Cebolla JJ; de Blas I; Roca M; Pocovi M; Giraldo P
PLoS One; 2015; 10(5):e0126153. PubMed ID: 25978039
[TBL] [Abstract][Full Text] [Related]
19. Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.
Lo SM; Stein P; Mullaly S; Bar M; Jain D; Pastores GM; Mistry PK
Am J Hematol; 2010 May; 85(5):340-5. PubMed ID: 20425796
[TBL] [Abstract][Full Text] [Related]
20. Response of Gaucher bone disease to enzyme replacement therapy.
Poll LW; Maas M; Terk MR; Roca-Espiau M; Bembi B; Ciana G; Weinreb NJ
Br J Radiol; 2002; 75 Suppl 1():A25-36. PubMed ID: 12036830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
